Clinical Trial Update: A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating MetMAb in combination with Tarceva for MET-positive non-small cell lung cancer has completed, with the trial status listed as complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MetMAb (onartuzumab)
• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED